secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-01-26T23:59:59+00:00
Accession:  0000950170-24-007703
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus announces Phase 1 data for CRB-701: 43% ORR at therapeutic doses, no peripheral neuropathy or skin rash
--------------------------------------------------------------------------------

- Phase 1 dose-escalation data for CRB-701 (SYS6002) in nectin-4 positive tumors presented at ASCO GU 2024.
- At doses ≥2.7 mg/kg (n=7), ORR 43% (3 partial responses) and disease control rate 71%; no grade 3+ adverse events.
- No dose-limiting toxicities, peripheral neuropathy, or skin rash observed; dose escalation ongoing at 4.5 mg/kg.
- CRB-701 showed lower free MMAE exposure vs enfortumab vedotin; longest ongoing response ~10 months.
- U.S. clinical study expected to start in Q1 2024 under already-open IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024007703/0000950170-24-007703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024007703/crbp-20240126.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-007703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer